AtheroGenics About
AtheroGenics: AtheroGenics
currently has two v-protectant® programs in clinical development targeting
atherosclerosis and organ transplant rejection. V
-Protectants® Block Activation of VCAM-1 in cells that line blood vessels.
V-Protectants®
are drugs that block a class of signals, called oxidant signals, which
are generated within endothelial cells. These oxidant signals activate genes,
which produce inflammatory proteins. The protein products of these selected genes,
including VCAM-1, attract white
blood cells to the site of chronic inflammation. This mechanism within arterial
blood vessel walls may control the excessive accumulation of white blood cells
without affecting the body's ability to fight infection Clinical
Trial Data --
Lead Compound Key
Statistics fo
Atherogenics
AtheroGenics is an emerging pharmaceutical company focused on the discovery, development
and commercialization of novel drugs for the treatment of chronic inflammatory
diseases, such as atherosclerosis,
rheumatoid arthritis and asthma.
Atherosclerosis
Coronary Artery Disease Myocardial Infarction Unstable Angina
Drug: AGI-1067
Phase III
NIH
Link
More on Atherogenics:
Basic Chart
for Atherogenics
Analyst
Opinion
Analysts
Estimates